XDx Cancels IPO

XDx Inc., a South San Francisco-based molecular diagnostics company that develops tests for the monitoring of transplant rejection and autoimmune diseases, has withdrawn its registration for an $86.25 million IPO. No reason was given. The company had planned to trade on the Nasdaq, with JPMorgan and Morgan Stanley serving as co-lead underwriters.


XDx has raised over $86 million in VC funding, from firms like Kleiner Perkins Caufield & Byers, TPG Ventures, Sprout Group, Burrill & Co., DAG Ventures, Integral Capital Partners and Intel Capital. www.xdx.com

Leave a Reply

PE HUB Community

Join the 12523 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget